- Home
- FENC vs CION Comparison
FENC vs CION Comparison
Compare FENC & CION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FENC | CION |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.3M | 363.1M |
| IPO Year | 2010 | 2011 |
Fundamental Metrics
Financial Performance| Metric | FENC | CION |
|---|---|---|
| Price | $12.30 | $7.31 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 1 |
| Target Price | ★ $14.50 | $7.00 |
| AVG Volume (30 Days) | 262.7K | ★ 414.1K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.96% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | $206.50 | ★ $17.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $5.83 |
| 52 Week High | $13.25 | $10.40 |
Technical Indicators
Market Signals| Indicator | FENC | CION |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 58.00 |
| Support Level | $9.74 | $7.18 |
| Resistance Level | N/A | $7.72 |
| Average True Range (ATR) | 0.57 | 0.17 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 71.73 | 49.45 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About CION CION Investment Corporation
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Companies portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.